logo
Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity
Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states
Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans
Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects
Human sympathetic activation by α2-adrenergic blockade with yohimbine
Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-α-methadol in opioid-naive individuals
Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine
Time response of cytochrome P450 1A2 activity on cessation of heavy smoking
Caution with β1-adrenergic receptor genotyping
Caution with β1-adrenergic receptor genotyping
A MESSAGE FROM THE ASCPT MEMBERSHIP COMMITTEE CHAIRPERSON